Related Experiment Video

Updated: May 4, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Axitinib

    Prescrire International
    |January 16, 2014
    PubMed

    Insights

    Interferon alfa and sunitinib extend survival for advanced kidney cancer patients. However, no treatments currently exist to prolong survival after sunitinib therapy fails.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Advanced-stage or metastatic kidney cancer presents significant treatment challenges.
    • Cytokines like interferon alfa and tyrosine kinase inhibitors (TKIs) are established therapies.

    Purpose of the Study:

    • To summarize the survival benefits of current treatments for advanced kidney cancer.
    • To identify unmet needs in the treatment landscape for metastatic kidney cancer.

    Main Methods:

    • Review of existing clinical data on interferon alfa, sunitinib, and sorafenib in kidney cancer treatment.
    • Analysis of survival data associated with sequential therapies.

    Main Results:

    • Interferon alfa prolongs survival by approximately 4 months.
    • Sunitinib offers a survival benefit of about 9 months.
    • Sorafenib may extend survival by an additional 3 months after interferon alfa failure.

    Conclusions:

    • Sunitinib demonstrates a significant survival advantage over interferon alfa.
    • There is a critical need for novel therapeutic strategies following sunitinib treatment failure in metastatic kidney cancer.

    More Related Videos

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    13.4K
    A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

    A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

    Published on: March 28, 2021

    2.3K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.0K
    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
    820
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    4.8K
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    689